World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Prequalification Unit Inspection Services
WHO PUBLIC INSPECTION REPORT
(WHOPIR)
Desk Assessment of Active Pharmaceutical Ingredient (API) Manufacturer

Part 1	**General information**
Company information	
Name of Manufacturer	Cipla Ltd, Patalganga API Unit II
Corporate address of manufacturer	Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013, India. Telephone: + 91 22 24826000 Web site: www.cipla.com
Contact person	P Gnanamoorthy Tel: +91 2192 660900 (Unit - I) / 660400 (Unit - II) Tel: +912192660900 (Unit- I)/ 660400 (Unit- II) *Email:* p.gnanamoorthy@cipla.com
Inspected site	
Name & address of manufacturing site	Cipla Ltd. Plot No.: A-33, A-2 & A-37/2/2 (Unit-I), A-42 (Unit-II) MIDC Patalganga, 410 220, District Raigad, Maharashtra, India. FEI NUMBER: 3002806710 Telephone: +91 2192 660900 (Unit - I) / 660400 (Unit - II) D-U-N-S Number: 916940208
Synthetic Unit/Block/Workshop	Unit II, plot A-42
Manufacturing license number	Number of license 25-KD/620 issued on 18.08.2021 valid till 17/08/2026
Desk assessment details	
Start and end dates of review	1 – 5 February 2025
Inspection record number	INSP-API-2018-0068
APIs covered by this desk assessment	APIMF004 Artesunate APIMF001 Lamivudine APIMF043 Artemether
Any documents missing?	Not applicable

Part 2	**Summary of SRA/NRA inspection evidence considered (from most recent to last) and comments**	
United States Food and Drug Administration (USFDA), US	Dates of inspection:	28 March – 04 April 2024
	Type of inspection:	NA
	Block/Unit/Workshop:	Units I and II.
	APIs covered:	The inspection report indicated that the firm produces and distributes API's and oral solid dosage forms for several markets, including the US. The report was included several exhibits including a list of finished drug products and for APIs that the firm has manufactured and distributed to all countries since the last inspection. As well as lists of the firm's products and APIs shipped to the US market.
	Physical areas inspected:	This inspection focused on the firm's Quality System, Production, Facilities and Equipment, Packaging and Labeling, and Laboratory Systems that serve as the foundation for production at the Patalganga site, Complaints and Recalls. The inspection included physical inspection of the firm's facilities and equipment, observation of manufacturing, review of records, and interviews with employees.
Part 3	**Summary of the last WHO inspection**	
Date and conclusion of most recent WHO inspection	The site was not inspected by WHO in the last 5 years. The last WHO inspection was made through desk assessment in 2020 and the site was concluded as complaint with WHO GMP guidelines.	

Abbreviations	**Meaning**
BMR	Batch manufacturing record
BPR	Batch production record
CAPA	Corrective and preventive action
CC	Change control
GMP	Good manufacturing practices
NC	Non conformity
NRA	National regulatory agency
PQR	Product quality review
PQS	Pharmaceutical quality system
QA	Quality assurance
QC	Quality control

QCL	Quality control laboratory
QMS	Quality management system
QRM	Quality risk management
RA	Risk assessment
RCA	Root cause analysis
SOP	Standard operating procedure

Part 4	**Summary of the assessment of supporting documentation**

a) Manufacturing authorization and GMP certificate granted by the local authority:

License issued from *Food & Drugs Administration (Maharashtra State).* Number of license 25-KD-620 issued on 18.08.2021 and valid up to: 17/08/2026 for plot A-42.

b) Site Master File (SMF):

A detailed SMF (SMF/CIP/PTG/A) with and effective date of 13th January 2025 was provided by the site. The SMF was complimented by 11 annexures including but not limited to; the Site Manufacturing authorization and GMP certifications, organization chart, site, plant and area classification layouts, list of non-sterile API and intermediates manufactured at the site, flow chart for manufacturing of APIs, list of the equipment and instruments for production and QC units was submitted and found acceptable and list of contracted testing laboratories. The SMF was reviewed and was found acceptable.

c) List of all the APIs or other products (intermediates, dosage forms) manufactured on-site:

A list of 10 products manufactured at the facility was provided. This was reviewed and no issues of concerns were found.

d) List of all regulatory inspections performed in the last 3 years and their outcomes:

Authority Inspection	Type	Date	Outcome
United States Food and Drug Administration (USFDA), US	GMP inspection	28 Mar – 4 Apr 2024	EIR issued with VAI classification
Pharmaceuticals and Medical Devices Agency (PMDA), Japan	Desk assessment	8 Mar 2024	Approved
ANVISA, Brazil	GMP inspection	10 – 14 Jul 2023	Approved
TGA, Australia	Desk assessment	13 Dec 2022	Approved
WHO-GMP, Central Drugs Standard Control Organisation (CDSCO)	Renewal	18 – 19 Jul 2022	Approved

e) Most recent product quality review(s) (PQR)(s) of the concerned WHO API(s):
The Annual product quality review (APQR) of covering the period from January to December 2024 was submitted.

The APQR of Artemether covering the period from June 2023 to May 2024 was also submitted. In addition, the APQR of Lamivudine USP covering the period from November 2023 to October 2024 was submitted.

The aforementioned APQRs were reviewed and found acceptable, in general.

f) Batch manufacturing and packaging record(s), including the analytical part, for the most recently released batch of relevant API(s):
Batch manufacturing and packaging records, including analytical data, for the most recent commercial batches of Artesunate, Lamivudine, and Artemether were reviewed and found acceptable. The following Batch Manufacturing Records (BMR), Batch Packaging Records (BPR), and analytical data were assessed:

- Artesunate (APIMF004)
  - Batch number: HWC220022
- Artemether (APIMF043)
  - Batch number: HWC230215
- Lamivudine (APIMF001)
  - Batch number: HWC180079

The reviewed documentation confirmed compliance with GMP requirements for batch production and control.

g) Master batch manufacturing and packaging record(s) of the API(s) of interest:
Batch manufacturing and packaging record(s), including the analytical part of the last commercial batches of Artemether, Artesunate and Lamivudine were submitted. These were generally found acceptable.

h) Recalls in the past three years related to APIs with quality defects:
The company provided a statement signed on 10 January 2025 confirming that no recalls have taken place until the application for desk assessment was submitted.

i) Confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the API(s) has been performed and all matters dealt with:
A letter was submitted signed on 3 January 2025 stating that self-inspections are conducted and CAPAs are implemented to ensure the status of compliance is maintained for all quality systems.

j) copy of any warning letter, or equivalent regulatory action, issued by any authority for their market, to which the site provides or has applied to provide the API(s):
A letter was submitted signed on 10 January 2025 by the company confirmed that no warning letters have been issued by any regulatory authorities against the site until the application for desk assessment was submitted.

k) Out-of-stock situations:
The company submitted a statement declaring that no out-of-stock situation is foreseen for WHO PQ products.

l) Additional documents submitted:
Not applicable

Part 5	Conclusion – Desk assessment outcome

Based on the previous United States Food and Drug Administration (USFDA inspection and on the GMP evidence received and reviewed, it is considered that a desk assessment is acceptable in lieu of a WHO onsite inspection. The site **Cipla Ltd, Patalganga API Unit II**, located at **Plot No.: A-42 (Unit-II), MIDC Patalganga, 410 220, District Raigad, Maharashtra, India** is considered to be operating at an acceptable level of compliance with WHO GMP guidelines.

This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.

Part 6	List of guidelines referenced in this inspection report

1. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-eighth Report Geneva, World Health Organization, 2014 (WHO Technical Report Series, No. 986), Annex 2.
   Short name: WHO TRS No. 986, Annex 2
   https://www.who.int/publications/m/item/trs986-annex2

2. WHO good manufacturing practices for active pharmaceutical ingredients. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 2.
   Short name: WHO TRS No. 957, Annex 2
   https://www.who.int/publications/m/item/annex-2-trs-957

3. WHO guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report. Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 9.
   Short name: WHO TRS 1010, Annex 9
   https://www.who.int/publications/m/item/trs1010-annex9

4. WHO Good Manufacturing Practices: water for pharmaceutical use. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report. Geneva, World Health Organization, 2021 (WHO Technical Report Series, No. 1033), Annex 3.
   Short name: WHO TRS No. 1033, Annex 3
   https://www.who.int/publications/m/item/annex-3-trs-1033

5. WHO guidelines for sampling of pharmaceutical products and related materials. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth Report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 4.
   Short name: WHO TRS No. 929, Annex 4
   https://www.who.int/publications/m/item/annex-4-trs-929

6. WHO good practices for pharmaceutical quality control laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-seventh Report. Geneva, World Health Organization, 2024 (WHO Technical Report Series, No. 1052), Annex 4.
   Short name: WHO TRS No. 1052, Annex 4
   https://www.who.int/publications/i/item/9789240091030

7. WHO Good Practices for Pharmaceutical Products Containing Hazardous Substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 3.
   Short name: WHO TRS No. 957, Annex 3
   https://www.who.int/publications/m/item/trs957-annex3

8. Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 8.
   Short name: WHO TRS No. 1010, Annex 8
   https://www.who.int/publications/m/item/Annex-8-trs-1010

9. Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. Part 2: Interpretation of Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-third Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1019), Annex 2.
   Short name: WHO TRS No. 1019, Annex 2
   https://www.who.int/publications/m/item/trs1019-annex2

10. WHO guidelines on transfer of technology in pharmaceutical manufacturing WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2022 (WHO Technical Report Series, No. 1044), Annex 4.
    Short name: WHO TRS No. 1044, Annex 4
    https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1044-annex4-technology-transfer-in-pharmaceutical-manufacturing.pdf

11. WHO good manufacturing practices for sterile pharmaceutical products. Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2022 (WHO Technical Report Series, No. 1044), Annex 4.
Short name: WHO TRS No. 1044, Annex 2
https://www.who.int/publications/m/item/trs1044-annex2

12. General guidelines for the establishment maintenance and distribution of chemical reference substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first Report Geneva, World Health Organization 2007 (WHO Technical Report Series, No.943) Annex 3. ***Short name: WHO TRS No. 943, Annex 3***
https://www.who.int/publications/m/item/trs943-annex3

13. WHO good practices for pharmaceutical microbiology laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 2.
Short name: WHO TRS No. 961, Annex 2
https://www.who.int/publications/m/item/trs961-annex2

14. WHO guidelines on quality risk management. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 2.
Short name: WHO TRS No. 981, Annex 2
https://www.who.int/publications/m/item/trs981-annex2

15. WHO guidelines on variation to a prequalified product. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 3.
Short name: WHO TRS No. 981, Annex 3
https://www.who.int/publications/m/item/annex-3-trs-981

16. WHO guidelines for drafting a site master file. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-Fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 14.
Short name: WHO TRS No. 961, Annex 14
https://www.who.int/publications/m/item/tr961-annex14

17. Good Manufacturing Practices: Guidelines on validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-third Report Geneva, World Health Organization, 2019 (WHO Technical Report Series, No. 1019), Annex 3.
Short name: WHO TRS No. 1019, Annex 3
https://www.who.int/publications/m/item/trs1019-annex3

18. WHO General guidance on hold-time studies WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 4.
Short name: WHO TRS No. 992, Annex 4
https://www.who.int/publications/m/item/trs992-annex4

19. Model guidance for the storage and transport of time-and temperature-sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 9.
Short name: WHO TRS No. 961, Annex 9
https://www.who.int/publications/m/item/trs961-annex9-modelguidanceforstoragetransport

20. WHO Technical supplements to Model Guidance for storage and transport of time – and temperature – sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 5.
Short name: WHO TRS No. 992, Annex 5
https://www.who.int/publications/m/item/trs992-annex5

21. WHO Recommendations for quality requirements when plant – derived artemisinin is used as a starting material in the production of antimalarial active pharmaceutical ingredients. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 6.
Short name: WHO TRS No. 992, Annex 6
https://www.who.int/publications/m/item/trs-992-annex-6

22. Guideline on data integrity. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2021 (WHO Technical Report Series, No. 1033), Annex 4.
Short name: WHO TRS No. 1033, Annex 4
https://www.who.int/publications/m/item/annex-4-trs-1033

23. WHO general guidance on variations to multisource pharmaceutical products. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report* Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 10.
Short name: WHO TRS No. 996, Annex 10
https://www.who.int/publications/m/item/trs966-annex10

24. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 10.
Short name: WHO TRS No. 1010, Annex 10
https://www.who.int/publications/m/item/trs1010-annex10

25. Points to consider when including Health-Based Exposure Limits in cleaning validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2021 (WHO Technical Report Series, No. 1033), Annex 2.
Short name: WHO TRS No. 1033, Annex 2
https://www.who.int/publications/m/item/annex-2-trs-1033

26. Points to consider for manufacturers and inspectors: environmental aspects of manufacturing for the prevention of antimicrobial resistance. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 6.
Short name: WHO TRS No. 1025, Annex 6
https://www.who.int/publications/m/item/trs-1025-annex-6

27. Production of water for injection by means other than distillation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 3.
Short name: WHO TRS No. 1025, Annex 3
https://www.who.int/publications/m/item/trs-1025-annex-3-water-for-injection

27. Good chromatography practice. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 4.
Short name: WHO TRS No. 1025, Annex 4
https://www.who.int/publications/m/item/trs1025-annex4

28. Good trade and distribution practices for pharmaceutical starting materials. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report* Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 6.
Short name: WHO TRS No. 996, Annex 6
https://www.who.int/publications/m/item/annex-6-trs-996

29. WHO guidelines for preparing a laboratory information file. *WHO Expert Committee on Specifications for Pharmaceutical Preparations.* Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 13.
Short name: WHO TRS No. 961, Annex 13
https://www.who.int/publications/m/item/trs961-annex13

30. WHO good manufacturing practices for excipients used in pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-seventh Report. Geneva, World Health Organization, 2024 (WHO Technical Report Series, No. 1052), Annex 1.
Short name: WHO TRS No. 1052, Annex 1
https://www.who.int/publications/i/item/9789240091030